Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a case of a 20-year-old woman revealed ectopic acanthosis nigricans at a post-syndactyly-release surgical site, suggesting this rare condition could result from epidermal–dermal mismatch and altered growth factor signaling in grafted skin, without indicating any metabolic or malignancy concerns.

In this case study, a 71-year-old woman with postmenopausal hirsutism was diagnosed with a Leydig cell tumor and endometrial carcinoma, with hirsutism improving one month after surgery.

This study found that AGA patients had higher serum and epidermal irisin levels, which were associated with metabolic syndrome, dyslipidemia, and abnormal carotid intima media thickness, suggesting potential irisin resistance affecting cardiometabolic health.

In this study, researchers observed a dose-dependent occurrence of persistent radiation-induced alopecia in patients with primary CNS tumors or head and neck sarcomas, noting distinctive patterns and features, and suggesting potential benefits of topical minoxidil and procedural interventions for treatment.

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

In this study, researchers found that patients with psoriasis had a higher probability of achieving and maintaining a clinical response using brodalumab compared to ustekinumab over 52 weeks, as measured by a multistate modelling approach based on absolute PASI scores.

This article discusses the potential of intralesional cidofovir as a treatment for SCC and reports no systemic toxicity, but highlights surgical excision as the most reliable curative option.

This case report examines a patient with myasthenia gravis, invasive thymoma, and paraneoplastic pemphigus associated with alopecia areata, notably without the usual mucosal involvement.

This case study identified a probable pure testosterone-secreting ovarian tumor in a woman with increased facial hair and elevated testosterone levels, confirmed by histological examination as Leydig cells hyperplasia, which normalized testosterone and symptoms post-surgery.

This case report describes a postmenopausal woman with virilization and an ovarian steroid cell tumor, highlighting the rarity and diagnostic importance of such tumors in this demographic.

In this case report, a 62-year-old postmenopausal woman with hyperandrogenism exhibited male-pattern alopecia and hirsutism, which improved after bilateral adrenal adenomas were removed, underscoring the need for investigation of androgen-producing tumors in similar cases.

This study describes a postmenopausal woman's diagnosis with ovarian hyperthecosis, confirmed by a GnRHa test normalizing testosterone, highlighting hormone therapy as a therapeutic option when surgery is not feasible.

This study found that intradermal injection of a specially designed RNA molecule, cp-asiAR, successfully reduced androgen receptor levels and promoted hair growth in a mouse model of androgenetic alopecia, while also improving hair follicle characteristics in ex vivo human scalp tissues without significant toxicity.

This case study reported that sudden hyperandrogenism in postmenopausal women may indicate hormonally active ovarian tumors such as Leydig cell tumors, which can be effectively treated with surgery.

This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.

In this case series, researchers reported scarring alopecia in six out of 450 patients (1.33%) treated with immune checkpoint inhibitors for metastatic melanoma, with all affected patients experiencing other immune-related adverse effects but continuing treatment with favorable cancer outcomes.

In this study, researchers reported that the SHBG +5790 G>A polymorphism was associated with an increased risk of developing resistance to hormonal castration in advanced prostate cancer patients.

This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.

This study found that the administration of the mutant BRAF inhibitor dabrafenib in patients with metastatic melanoma was associated with various skin lesions, including keratinocytic proliferation that sometimes showed low-grade malignancy features.

Werner's syndrome causes early aging and increases cancer risk, requiring early diagnosis and symptom management.

This study reported that targeted anticancer therapies are associated with an increased risk of alopecia compared to placebo, although the risk was lower compared to chemotherapy.

In this study, the lack of cathepsin expression in Kaposi's sarcoma lesions suggests a benign hyperplastic origin for these lesions.

This study found that mesenchymal stem cells sourced from hair follicle outer root sheath showed higher differentiation efficiency and angiogenic potential for vascular graft applications compared to adipose-derived stem cells.

This study created a novel classification for dermatological and cosmiatric changes caused by cancer treatments, categorizing them as triggered, exacerbated, or unrelated to the treatment.

This case report highlights the importance of suspecting underlying malignancy, such as Hodgkin's lymphoma, in patients with diffuse hair loss and other cutaneous symptoms.

This report describes a clinical case of a 38-year-old man diagnosed with Birt-Hogg-Dubé syndrome, confirmed by genetic testing, highlighting the presentation of multiple renal tumors and bilateral lung cysts.

This study identifies SOX9 as a critical downstream effector of ERG in TMPRSS2:ERG fusion-positive prostate cancer, indicating its role in tumor invasion and growth.

In this study, early-onset androgenetic alopecia in men was associated with a higher prevalence of metabolic syndrome and carotid atherosclerosis compared to controls, suggesting cardiovascular screening might be beneficial for this group.

This article compiles references on toxic epidermal necrolysis and cutaneous reactions to anticancer agents but reports no new findings.

Temporary hair loss can occur after brain AVM treatment but usually regrows in 8 weeks.